Ipsen SA

IPN: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|p>LOCK|CPWk&LOCK|#<YmZ?

Ipsen: Portfolio Expansion Adds Value as Somatuline Faces Generic Pressure

Ipsen completed its acquisition of Memo Therapeutics, which added potravitug, a phase 2 rare-disease therapy. Ipsen is also on track to close its acquisition of Kartos Therapeutics, which will add navtemadlin, a phase 3 candidate for myelofibrosis.

Sponsor Center